Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
02/2005
02/17/2005US20050037460 Potassium channels and genes encoding these potassium channels
02/17/2005US20050037458 Secreted and transmembrane polypeptides and nucleic acids encoding the same
02/17/2005US20050037457 Expression vector comprising nucleotide sequences coding fibroblast growth factor for use in diagnosis, prevention and treatment of cell proliferative, liver, reproductive and urogenital disorders
02/17/2005US20050037454 Expression vector comprising nuclelotide sequences coding osteoblast protein for use in diagnosis, prevention and treatment of osteoporosis and bone resorption disorders
02/17/2005US20050037448 C-peptide specific assay procedure
02/17/2005US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer
02/17/2005US20050037444 Method for identification isolation and production of antigens to a specific pathogen
02/17/2005US20050037443 Detection of sarcocystis neurona
02/17/2005US20050037442 Cells transfected with nucleotide sequences that code for mutant mammalian proteins or polypeptides, used for screening antiarrhythmic agents
02/17/2005US20050037436 Test systems and the use thereof for identifying and characterizing compounds
02/17/2005US20050037432 Macroglobulin peptides for use as diagnostic indicator of osteoarthritis, bone and tissue disorders
02/17/2005US20050037431 Methods and compositions for modulating HGF/Met
02/17/2005US20050037430 creating a peptide database by screening, analyzing the results, characterizing a physical, chemical, or biological property of the peptides, recording; using a computer for presenting biomolecular sequence data; regulatory activity on pro- or anti-inflammatory cytokine cascades; immunoresponse
02/17/2005US20050037427 Structure for presenting desired peptide sequences
02/17/2005US20050037425 mmFP encoding nucleic acids, polypeptides, antibodies and methods of use thereof
02/17/2005US20050037422 Synthetic peptides and dna sequences for treatment of multiple sclerosis
02/17/2005US20050037419 Compositions and methods relating to lung specific genes and proteins
02/17/2005US20050037416 Hybrid nucleic acid; isolation antibody
02/17/2005US20050037412 Thermostable Taq polymerase fragment
02/17/2005US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity
02/17/2005US20050037399 nucleic acid having a specific nucleotide sequence, used to diagnose or determine predisposition to adenocarcinoma.
02/17/2005US20050037395 Product
02/17/2005US20050037385 Genetically engineered protein comprising multiple zinc finger domains for use as regulatory quadruplets in gene expression analysis
02/17/2005US20050037383 Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
02/17/2005US20050037380 Novel receptor-type phosphotyrosine phosphatase-alpha
02/17/2005US20050037379 Reagents and methods useful for detecting diseases of the prostate
02/17/2005US20050037378 CARD3X-2 polypeptides, encoding nucleic acids, and methods of use
02/17/2005US20050037372 Expression vector comprising nucleotide sequences coding immunglobulin which binds nuclear matrix protein for use in generating diagnosing, classifiyiing and prognosing hepatic cell proliferative disorders
02/17/2005US20050037360 Materials and methods for inhibiting wip1
02/17/2005US20050037355 Measuring intracellular adenosine triphosphate and/or gene expression in transgenic cell via monitoring luciferin bioluminescent signals; genetiic engineering and reporter molecules
02/17/2005US20050037347 Novel cancer-associated genes
02/17/2005US20050037346 Distinguish minority template in the presence of an excess of normal template with a thermostable ligase; useful for the detection of cancer-associated mutations; quantitative measure of the amount or ratio of minority template; a thermostable mutant ligase
02/17/2005US20050037345 Gene with polynucleopotide codes with polypeptide with amino acid sequences for domains and molecular hybridization for gene expression and cancer
02/17/2005US20050037340 Immunoglobulin for use in detection of simian and lymphadenopathy associated viral infection in mammals; immunodiagnostics
02/17/2005US20050037339 Methods of selecting internalizing antibodies
02/17/2005US20050037337 Papilloma virus sequences
02/17/2005US20050037336 Hepatitis X virus for use in generation of antibody and vaccine compositions for use in diagnosis, prevention and treatment viral infection; immunotherapeutic and diagnostics
02/17/2005US20050037026 such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier
02/17/2005US20050037022 With improved shelf life and storage stability; expression vectors and host cells; therapeutic proteins are chemically or genetically fused to albumin
02/17/2005US20050037021 For primates; p42 nucleic acid encoding a p42 polypeptide from the C-terminal processing fragment of Plasmodium falciparum major merozoite surface protein gp195 which hybridizes under high stringency conditions
02/17/2005US20050037020 Hydrophilic eimeria polypeptide; genetic engineering
02/17/2005US20050037019 Vaccines for Chlamydia psittaci infections
02/17/2005US20050037018 Vaccination with a synergistic combination of a Hepatitis C Virus E1 vaccine and an antiviral agent, such as an interferon; improved immunostimulation
02/17/2005US20050037017 Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
02/17/2005US20050037016 determining whether a mouse is infected with murine norovirus-1 by determining presence, absence or quantity of antibody against MNV-1 a sample of a mouse; the antibody binds to MNV-1 deposited as American Type Culture Collection (ATCC) Deposit No. PTA-5935 or to a polypeptide encoded by it
02/17/2005US20050037014 T helper cell epitopes
02/17/2005US20050037012 A polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity
02/17/2005US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
02/17/2005US20050037009 Methods and reagents for protease inhibition
02/17/2005US20050037008 unexpected discovery that the inhibition or antagonism of TNF decreases the expression of Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF). VEGF has been implicated in the angiogenesis in cancer, vascular diseases and rheumatoid arthritis
02/17/2005US20050037005 5c8 Antigen
02/17/2005US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents
02/17/2005US20050036999 Novel receptor-type phosphotyrosine phosphatase-alpha
02/17/2005US20050036997 Molecular modeling of the binding sites for anisomycin, azithromycin, erythromycin, linezolid, tylosin, carbomycin A, spiramycin, virginiamycin, sparsomycin and blasticidin using the Haloarcular marismortui large ribosomal subunit; drug design and drug screening
02/17/2005US20050036995 Immunogens; tumor antigens; kits
02/17/2005US20050036986 Antisense agents; gene expression inhibition; prostate cancer; hyperplasia; carcinoma
02/17/2005US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/17/2005US20050036948 Radiolabeled annexins
02/17/2005US20050036942 killing a prostate stem cell antigen (PSCA) expressing cancer cell, comprising contacting the cancer cell with an isolated PSCA antibody that internalizes upon binding to PSCA on a mammalian cell in vivo; prostate cancer, bladder cancer and lung cancer
02/17/2005DE10332854A1 Verwendung des neu-identifizierten humanen Gens 7a5/Prognostin für Tumordiagnostik und Tumortherapie Using the newly-identified human gene 7a5 / Prognostin for tumor diagnosis and tumor therapy
02/17/2005DE10332685A1 Use of a modulator of specific potassium channels, expressed preferentially in the atrium, for treatment and prevention of arrhythmia, coronary disease and hypertension
02/17/2005CA2844154A1 Polysaccharide-protein conjugate vaccines
02/17/2005CA2827128A1 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
02/17/2005CA2678736A1 Novel multifunctional il-2 - il-18 fusion proteins
02/17/2005CA2555323A1 Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide
02/17/2005CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer
02/17/2005CA2535517A1 Product comprising a c4bp core protein and a monomeric antigen, and its use
02/17/2005CA2535045A1 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
02/17/2005CA2534909A1 P16 mediated regulation of nmda receptors
02/17/2005CA2534900A1 Process for preparing an alpha-1-antitrypsin solution
02/17/2005CA2534894A1 Fungus resistant plants and their uses
02/17/2005CA2534812A1 Mutations in ion channels
02/17/2005CA2534739A1 Complexes of gpcr142 and relaxin3 or insl5, and their production and use
02/17/2005CA2534708A1 Targeted carrier fusions for delivery of chemotherapeutic agents
02/17/2005CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy
02/17/2005CA2534412A1 Conjugates of a polymer and a protein linked by an oxime linking group
02/17/2005CA2534355A1 Compounds comprising lpa
02/17/2005CA2534352A1 Methods of protein production in yeast
02/17/2005CA2534296A1 Methods and compositions for targeted cleavage and recombination
02/17/2005CA2534143A1 Method of peptide synthesis
02/17/2005CA2533557A1 Novel peptide interacting with anti-apoptotic proteins of a bcl-2 family
02/17/2005CA2533149A1 Il-11 muteins
02/17/2005CA2532759A1 Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases
02/17/2005CA2532721A1 Ra antigenic peptides
02/17/2005CA2532312A1 Process for the production of fine chemicals in plants
02/17/2005CA2531916A1 Animal model for the analysis of tumor metastasis
02/17/2005CA2531773A1 Novel multifunctional cytokines
02/17/2005CA2531228A1 Novel therapeutic fusion proteins
02/17/2005CA2530482A1 Self-assembling peptides incorporating modifications and methods of use thereof
02/17/2005CA2529623A1 Antibodies specific for sclerostin and methods for increasing bone mineralization
02/17/2005CA2528569A1 Method for producing a polypeptide
02/17/2005CA2526900A1 Truncated fragments of alpha-synuclein in lewy body disease
02/17/2005CA2526274A1 Prostate stem cell antigen (psca) variants and subsequences thereof
02/17/2005CA2523676A1 Dna vaccine expressing ha1 of equine-2 influenza virus
02/17/2005CA2517489A1 Novel protein usable in screening drug improving diabetes
02/16/2005EP1507007A1 Cell cycle related proteins
02/16/2005EP1507006A1 Method of screening remedy for renal failure
02/16/2005EP1507003A1 Process for producing protein in cell-free protein synthesis system using thioredoxin fused protein expression vector
02/16/2005EP1507002A2 Thermostable Taq polymerase fragment
02/16/2005EP1506972A1 Insulin-like growth factor (IGF) I mutant variants